Dr Leora Fox
Editor-in-chief
New York, USA
Leora Fox oversees research and patient engagement programs at the Huntington’s Disease Society of America (HDSA). She got her PhD in 2016 at Columbia University, where she studied Huntington’s disease mouse models and how brain cells dispose of huntingtin protein. She worked in Medical Communications prior to joining HDSA in August of 2017. Dr. Fox supports HDSA’s efforts towards funding Huntington’s disease research, communicating HD research news, and amplifying family voices in the process of HD drug development. She is passionate about communicating science to the HD community so that families understand scientific progress in HD, can make informed decisions about participating in clinical research, and are supported around research news.
Articles edited by Dr Leora Fox
- A new era for HDBuzz
- Cry your eyes out: detecting huntingtin in tears
- Understanding expansions at the single cell level
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- Putting it in print: GENERATION HD1 study results published
- Beyond huntingtin lowering: out-of-the-box approaches for the treatment of HD
- Getting to the Root of Huntington's Disease: A Plant-Based Approach
- Could halting CAG expansions be a new treatment for HD?
- Youthful competitors: young brain cells oust the old
- Astrocytes: The new star in HD research?
- Roche Phase II GENERATION HD2 study underway
- Focusing in on fibrils; scientists give us a glimpse of huntingtin protein clumps
- A new roadmap to track Huntington’s disease progression
- Shining a spotlight on huntingtin: a tool to measure huntingtin-lowering in real time
- A first for CRISPR gene editing could have wider applications for human disease
- Scientists identify precisely how pridopidine works in models of Huntington’s disease
- Huntington’s disease clinical trial round up
- Sad News from Roche and Ionis - ASO Trial Halted Early
- GPR52: Exploring a new way to lower huntingtin
- Uncovering the dark side of DNA repair to design HD treatments
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 1
- Treatment for neurological disorder could be repurposed for Huntington’s disease patients
- Caution urged for the use of gene-editing technology CRISPR
- Changing jobs: converting other cell types into neurons
- Fountain of youth: HTT protein repairs neurons by maintaining youthful state
Articles written by Dr Leora Fox
- A new era for HDBuzz
- Huntington's Disease Therapeutics Conference 2024 - Day 3
- Huntington's Disease Therapeutics Conference 2024 - Day 2
- Huntington's Disease Therapeutics Conference 2024 - Day 1
- Steady progress from uniQure - promising data to end the year
- Putting it in print: GENERATION HD1 study results published
- Drug to treat movement symptoms of HD approved by FDA
- Updates from PTC Therapeutics and uniQure on their huntingtin-lowering trials
- Start here!
- Huntington’s disease therapeutics conference 2023 - Day 3
- Huntington’s disease therapeutics conference 2023 - Day 2
- Huntington’s disease therapeutics conference 2023 - Day 1
- Hunting for balance: how the huntingtin protein compensates in HD
- uniQure gets the green light to resume testing HD gene therapy
- Update on the PTC Therapeutics PIVOT-HD Trial
- Forward momentum for Roche and Wave in latest news about huntingtin-lowering trials
- Hereditary Disease Foundation (HDF) conference 2022 – Day 3
- Hereditary Disease Foundation (HDF) conference 2022 – Day 2
- Sad news from Novartis: dosing suspended in VIBRANT-HD trial of branaplam
- Updates from uniQure about their gene therapy for Huntington's disease
- Huntington’s disease therapeutics conference 2022 - Day 2
- Huntington’s disease therapeutics conference 2022 - Day 1
- Revisiting vitamin therapy for HD
- Huntington’s disease therapeutics conference 2022 - Day 3
- Finding the silver lining: an update on the Roche GENERATION-HD1 trial data
- Real talk: Q&A with Roche about GENERATION-HD1
- Another tool in the box: Creation of a molecular “dimmer switch” advances gene editing
- Unpacking recent gene therapy press
- Huntington's disease therapeutics conference 2021 - Day 3
- Huntington's disease therapeutics conference 2021 - Day 2
- Huntington’s disease therapeutics conference 2021 - Day 1
- Good news from uniQure: gene therapy trial on track, and promising data in animals
- Disappointing Results from Wave’s PRECISION-HD1 and 2 Trials
- Huntington Study Group (HSG) 2020 Annual Conference: HD in Focus - Day 2
- When genes are unstable: targeting somatic instability in HD
- HD and Histamines: Targeting Hybrid Receptors to Quiet Stressful Brain Talk
- HDSA FAQ on the Roche/Genentech RG6042 program
- HDSA’s Q&A on the latest huntingtin-lowering update from Ionis and Roche
- New roles for huntingtin: removing a healthy protein to understand its function
- A step forward for gene editing: CRISPR-Cas9 and HD
- New study reveals a potential HD biomarker
- Sheep leading the flock: metabolism and biomarkers in HD
- Huntingtin grabs a hammer: DNA repair in HD
- Huntingtin takes a trip: harmful proteins pass between brain cells
- Important drug targets yielded by new genetic study of HD
- Harnessing the power of viruses to treat Huntington's disease
- A recycled drug gives us new insight in to HD
- Through the eyes of a friend: changes in mood and behavior in early HD
- Mapping the anatomy of HD: a whole-brain history
- Would ewe believe it? GM1, sheep and Huntington's disease
- Novel research technique suggests an antioxidant gene protects vulnerable neurons
- Huntington's disease clinical trial announcement: huntingtin-lowering drug to enter Phase I trial in 2015
- Melatonin alterations in Huntington's disease help explain trouble with sleep
- Joint HDBuzz Prizewinner: Yeast studies suggest a new way to protect cells from 'oxidative damage'